Aurinia Pharmaceuticals Downgraded by Bloom Burton & Co. Amidst Strategic Review and Workforce Reduction
On Friday, Bloom Burton & Co. adjusted its stance on Aurinia Pharmaceuticals, downgrading the stock to Hold from its previous rating of Buy, while also reducing the price target to $8 from $13. The revision follows a strategic review initiated in June 2023 that failed to secure a formal offer to acquire the company.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
